Read

What Brokers and TPAs Need To Know About Humira Biosimilars

Below is an excerpt from an article by AlignRx chief pharmacy officer Beckie Fenrick and Goodroot area vice president of business development Brian Shonat that was recently published in BenefitsPRO. Following decades of patent litigation and maneuvering, the first biosimilar to Humira is now available with many more to follow this year. Humira is a […]

What Brokers and TPAs Need To Know About Humira Biosimilars Read More »

A Shake Up in the U.S. Insulin Market: Major Manufacturers Lower Insulin Costs

A new trend in insulin pricing? Here’s what you need to know. Insulin pricing has been a topic of concern and debate in recent years, as prices have skyrocketed, making it difficult for many patients with diabetes to afford the medication they need. However, the following recent announcements from major pharmaceutical manufacturers—who make up about

A Shake Up in the U.S. Insulin Market: Major Manufacturers Lower Insulin Costs Read More »

Whitepaper: Breaking Down the Hottest Topic in Pharmacy—Humira Biosimilars

The industry report you’ve been waiting for. Today biosimilars seem to be the topic of conversation everywhere. Why? Humira. The launch of Humira biosimilars will be a test for industry stakeholders, as their entrance will reveal whether blockbuster drugs—that offer significant rebates—can be replaced to reduce the cost burden on patients and payers in the United States. Download our

Whitepaper: Breaking Down the Hottest Topic in Pharmacy—Humira Biosimilars Read More »

RxDC TPA Guide – What TPAs Need to Know

The RxDC Reporting Deadline Is Approaching—Are You Prepared? The Consolidated Appropriations Act has a new Rx mandate for your employer groups and the deadline is approaching—are you prepared? The new mandate requires employer-based health plans to submit information about prescription drug and healthcare spending to the Departments of Health & Human Services, Labor, and the

RxDC TPA Guide – What TPAs Need to Know Read More »

How Specialty Drug ‘Solution Stacking’ Can Rein in Pharmacy Benefit Costs

Brokers and employer groups alike know that 5% to 10% percent of insured workers and their dependents drive 50% to 60% of the cost of pharmacy claims. A few members with prescriptions for a specialty drug with a five-figure price tag can easily represent the majority of an entire group’s pharmacy spend. These drugs are

How Specialty Drug ‘Solution Stacking’ Can Rein in Pharmacy Benefit Costs Read More »

Prediabetes and Type 2 Diabetes Screening

What is happening:  In August 2021 the United States Preventive Services Task Force (USPSTF) recommended that adults, aged 35 to 70 years who are overweight or obese, be screened for prediabetes or type 2 diabetes. In addition to these screenings, USPSTF recommended that clinicians should offer patients with prediabetes effective preventive interventions. Preventive interventions include

Prediabetes and Type 2 Diabetes Screening Read More »

What Employers, TPAs and Brokers Need to Know About COVID 10 Home Testing

January 10, 2022, the U.S. Department of Labor (DOL) issued guidance related to insurance coverage for COVID OTC testing, provided at no cost to covered individuals that was effective as of January 15, 2022. COVID 10 Home Testing Highlights Beginning January 15, 2022, most individuals with health insurance can purchase at home over-the-counter COVID-19 diagnostic

What Employers, TPAs and Brokers Need to Know About COVID 10 Home Testing Read More »

How Digital Therapeutics Are Paid For Has Huge Implications

Digital Therapeutics (DTx) have been increasingly popular since smartphones and wearable tech have become ubiquitous. The pandemic has set them on a trajectory for massive growth and mainstream adoption. Currently, there is inconsistency in how DTx are handled by payers and health plans. We are at a critical juncture to set precedents that make sense

How Digital Therapeutics Are Paid For Has Huge Implications Read More »